Abstract
Hormonal treatment combined with radical prostectomy has shown clinical benefits in patients with localized prostate cancer. However, hormone therapy as adjuvant treatment provides significant survival advantages only in patients with lymph nodes involvement. In others, this treatment is associated with an improvement in survival without biochemical progression but it does not improve specific survival. Consequently, the use of adjuvant hormone therapy should be restricted to patients with lymph node invasion.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
